FDA approves first postpartum depression drug

For the first time in history, the US Food and Drug Administration has approved a drug specifically indicated for the treatment of postpartum depression, which experts say offers new hope to women and physicians. The FDA announced the approval of an intravenous infusion of the drug brexanolone, which will be sold as Zulresso. It has been shown in clinical trials to work within hours to treat the symptoms of postpartum depression, a serious mental illness that impacts 1 in 9 new mothers after childbirth. CNN's Dr. Sanjay Gupta reports.

Posted: Mar 20, 2019 8:18 AM


For the first time in history, the US Food and Drug Administration has approved a drug specifically indicated for the treatment of postpartum depression, which experts say offers new hope to women and physicians.

On Tuesday, the FDA announced the approval of an intravenous infusion of the drug brexanolone, which will be sold as Zulresso. It has been shown in clinical trials to work within hours to treat the symptoms of postpartum depression, a serious mental illness that impacts 1 in 9 new mothers after childbirth.

The treatment is administered as a single 60-hour IV drip and was found to have mild side effects, such as headache, dizziness or excessive sleepiness. Yet some women may face barriers accessing this type of treatment, as it requires 60 hours of time. The drug will likely be priced around $20,000 to $35,000 per treatment, Sage Therapeutics, the company that developed the drug, confirmed.

The initial list price for Zulresso in the United States will be $7,450 per vial, resulting in a projected average course of therapy cost of $34,000 per patient before discounts, according to the company. The actual number of vials used before discounts can vary from patient to patient.

The medication will be available in June, said Dr. Jeff Jonas, CEO of the Massachusetts-based biopharmaceutical company that developed the drug. The drug will be available only through a restricted program called the Zulresso Risk Evaluation and Mitigation Strategy (REMS) Program that requires the drug be administered by a health care provider in a certified health care facility, the FDA said in a news release announcing the approval.

"There are no FDA approved antidepressants for postpartum depression, so approval of the first medication of its kind is a breakthrough for patients," said Dr. Kristina Deligiannidis, the director of Women's Behavioral Health at Northwell Health's Zucker Hillside Hospital in New York, who was involved in two of the drug's clinical trials as a researcher.

Without any treatment, postpartum depression can last for months or even years, according to the National Institute of Mental Health. Studies showed the brexanolone was effective regardless of when postpartum depression symptoms began.

In the United States, it's estimated that every year, more than 400,000 infants are born to mothers who are depressed. Treatment options for postpartum depression have included counseling or therapy with a mental health professional and antidepressant medications, but no antidepressant medication has been specifically FDA-approved to treat postpartum depression. Also, antidepressant medications generally don't provide an immediate relief of symptoms and may take several weeks to help.

"Brexanolone in phase II and III trials demonstrated rapid antidepressant effects," said Deligiannidis, who is also an associate professor at the Feinstein Institute for Medical Research and member of the Anxiety and Depression Association of America.

Those effects are something that Stephanie Hathaway, a Connecticut-based mother of two, knows well.

A 'breakthrough' drug gets tested

When Hathaway brought her first baby home from the hospital, she was just as excited and nervous as most new moms -- but she also experienced crying spells and troubling thoughts that she couldn't shake.

"The first two weeks I was crying excessively," Hathaway said. At first, her husband and she thought her tears were from "the baby blues," a feeling of sadness or emptiness after giving birth that goes away within a few days.

"But after that I had intrusive thoughts," she said. "Those were, 'Your daughter deserves a better mom,' and 'Your husband deserves a better wife.' "

Then Hathaway knew she needed help when one day she was holding her daughter and she feared what she might do to herself once she put her baby down.

That year, in 2014, Hathaway was diagnosed with postpartum depression and was treated with traditional antidepressant medications, which she said helped "over time."

A few years later, in 2017, Hathaway had a second child, and was prescribed the same antidepressants during that pregnancy -- but the medications were not helpful in relieving her symptoms.

A friend told Hathaway about clinical trials being conducted to evaluate the effectiveness of brexanolone in treating postpartum depression. Hathaway enrolled in a trial.

"It was a 60-hour infusion and in the first 12 to 18 hours I felt the biggest difference," Hathaway said.

"Those intrusive thoughts that played on repeat in my head, those went away and didn't come back," she said, adding that as a side effect, "I just had one very small instance of standing up and feeling lightheaded."

In 2016, the FDA granted brexanolone a "breakthrough therapy designation" for the treatment of postpartum depression. Such a designation is intended to expedite the development and review of drugs for serious or life-threatening conditions.

Results from two phase III trials of brexanolone, conducted across 30 clinical research centers and specialized psychiatric units in the United States, published in the journal The Lancet in August.

The trials, conducted in 2016 and 2017, involved more than 200 women who had symptoms of postpartum depression, which were assessed by standardized research scales. The women were followed up with over 30 days. Sage Therapeutics funded the research.

In those studies, some of the women were given 60-hour IV infusions of smaller or larger doses of brexanolone while others were given a placebo. The researchers found that the women who received brexanolone infusions had "significant and clinically meaningful" reductions in their depression scores.

In the first study, by the end of 60 hours, the average reduction was 19.5 points in the brexanolone group that received smaller doses, and 17.7 points in the brexanolone group that received larger doses, compared with 14 points in the placebo group.

In the second study, which had only one brexanolone group, the average reduction in score was by 14.6 points in the brexanolone group compared with 12.1 points in the placebo group at 60 hours, the researchers found.

Overall, at 60 hours, about 75% of women who received brexanolone were at least 50% improved in their symptoms and about half of women who received brexanolone were no longer clinically depressed, Deligiannidis said.

Among the patients who had a response at 60 hours, 94% did not relapse at the 30-day followup.

The most common side effects included headache among 15.7% of patients; dizziness among 13.6%; and somnolence or excessive sleepiness among 10.7%, the researchers found.

The researchers wrote in the study that their findings "provide strong evidence for the efficacy and safety of brexanolone injection in women with moderate to severe post-partum depression."

Limitations of the studies include that the women were followed only for 30 days, so the duration of treatment effects beyond that were not included in the data.

The treatment also requires 60 hours of an IV -- which, for women without support at home or living in poverty, could be difficult. Low-income mothers are at high risk for postpartum depression. The treatment also could interrupt breastfeeding, and patients are encouraged to discuss the risks and benefits of breastfeeding with their physician.

Additionally in the trials, brexanolone had the most robust effects on women experiencing severe postpartum depression whereas results were more modest among others whose postpartum depression was less severe.

'It potentially sets a new standard for treatment'

"What has been consistent is that brexanolone had a very robust response -- and what's been most exciting to me, in terms of participating in this new drug development, was the rapid onset of response. The drug works quickly," said Dr. Samantha Meltzer-Brody, a professor of mood and anxiety disorders at the University of North Carolina School of Medicine in Chapel Hill, who was a researcher in those phase III trials for the drug.

"My greatest hope is that this increases awareness. What's heartbreaking is the number of women who suffer in silence and do not get the treatment that they need," she said. "People need to reach out and get screened and get treatment, regardless of if treatment is with brexanolone or not."

The clinical data supporting the effectiveness of brexanolone in helping women recover from postpartum depression sheds new light on the neurobiology of the illness, as well as depression during other life periods, said Catherine Monk, professor of medical psychology in obstetrics and gynecology and psychiatry at Columbia University Irving Medical Center and director of research in the women's program in psychiatry at NewYork-Presbyterian/Columbia University Irving Medical Center in New York. Monk was not involved in the drug trials.

Monk, who is also a research scientist at the New York State Psychiatric Institute, added that "because its effects are truly expedited, within days, it potentially sets a new standard for treatment for severe postpartum depression."

Indiana Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 150664

Reported Deaths: 4008
CountyConfirmedDeaths
Marion24697784
Lake13220352
St. Joseph8877159
Elkhart8469132
Allen7880222
Hamilton5962113
Vanderburgh559360
Tippecanoe354714
Monroe320738
Hendricks3183130
Johnson2995128
Porter297848
Clark285461
Delaware282074
Vigo252637
Madison229593
Cass222021
LaPorte215557
Warrick188464
Kosciusko176823
Floyd174867
Howard158866
Bartholomew139758
Dubois135125
Marshall132526
Henry122628
Grant120939
Wayne119327
Boone118848
Hancock114145
Noble113533
Jackson108713
Morgan92240
Dearborn91628
Daviess84033
Gibson83411
Clinton81616
Shelby79429
Lawrence78534
LaGrange76715
Harrison74024
Putnam71016
Knox70310
DeKalb69411
Posey6796
Steuben6008
Fayette58517
Miami5845
Montgomery57222
White56815
Jasper5624
Greene51837
Scott50813
Decatur49839
Adams4725
Clay4346
Whitley4316
Sullivan42812
Ripley4228
Wells4155
Starke3937
Wabash3919
Orange38725
Huntington3785
Spencer3706
Franklin36525
Jennings36013
Washington3592
Randolph3398
Fulton3362
Jefferson3305
Pike31913
Carroll31413
Perry29514
Jay2876
Fountain2863
Tipton26823
Parke2203
Newton21811
Vermillion2181
Rush2044
Owen2021
Martin1950
Blackford1923
Crawford1491
Pulaski1471
Brown1303
Ohio1227
Benton1070
Union1040
Switzerland890
Warren751
Unassigned0233

Ohio Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 185639

Reported Deaths: 5083
CountyConfirmedDeaths
Franklin30978635
Cuyahoga19436675
Hamilton16234338
Montgomery10083186
Lucas8175370
Butler8028123
Summit6555261
Warren406360
Stark3696178
Mahoning3635283
Marion335149
Pickaway296946
Delaware281127
Lorain266689
Fairfield257856
Licking248865
Wood244681
Clark242454
Clermont234937
Trumbull2221134
Greene219640
Columbiana210187
Allen203873
Miami195656
Lake188357
Medina180242
Portage156167
Mercer147128
Ross133833
Wayne131568
Richland128624
Tuscarawas123622
Athens11742
Erie113853
Darke110151
Madison103514
Hancock103023
Auglaize95116
Putnam91527
Lawrence90725
Shelby86814
Muskingum8434
Geauga83650
Scioto8059
Belmont78427
Union7343
Ashtabula72148
Huron69910
Sandusky69422
Preble59517
Seneca58514
Holmes57010
Ottawa56830
Fulton5056
Jefferson4564
Henry45317
Defiance44413
Jackson4417
Clinton43613
Fayette4328
Crawford4308
Highland4024
Logan4023
Champaign3873
Ashland3735
Brown3683
Knox36215
Perry35411
Washington33323
Morrow3312
Hardin32113
Williams3194
Coshocton29812
Pike2880
Guernsey2878
Wyandot28413
Gallia27913
Van Wert2333
Meigs21012
Adams2036
Carroll1917
Paulding1901
Hocking1899
Monroe15218
Noble1210
Vinton903
Harrison793
Morgan740
Unassigned00
Fort Wayne
Overcast
54° wxIcon
Hi: 59° Lo: 50°
Feels Like: 54°
Angola
Overcast
52° wxIcon
Hi: 58° Lo: 47°
Feels Like: 52°
Huntington
Overcast
54° wxIcon
Hi: 58° Lo: 52°
Feels Like: 54°
Decatur
Overcast
55° wxIcon
Hi: 60° Lo: 52°
Feels Like: 55°
Van Wert
Overcast
55° wxIcon
Hi: 61° Lo: 51°
Feels Like: 55°
Warmer Thursday
WFFT Radar
WFFT Temperatures
WFFT National

Community Events